elevated pH (24,25) may enhance the affinity of HSA for warfarin by up to threefold but the molecular mechanisms of these effects are not well understood.
To elucidate the molecular details of the interaction of warfarin with HSA, we report here the determination of the crystal structures of HSA-myristate complexed with both the R-(+) and S-(-) enantiomers of the drug.
Experimental procedures
Purification, crystallisation and drug soaking. Purified recombinant HSA, produced in yeast and supplied by Delta Biotechnology Ltd. (Nottingham, UK), was purified, complexed with excess myristic acid and crystallised as described previously (11,12). Racemic warfarin, purchased from Sigma-Aldrich (A-2250) was separated into R-(+) and S-(-) enantiomers using established protocols (26).
Crystals of HSA-myristate were harvested into solutions containing 37% (w/v) polyethylene glycol 3350, 50 mM potassium phosphate. Warfarin was dissolved at 20 mM in harvest buffer at pH 12.0 with continuous stirring for 24 hours; the pH was then restored to 7.0 with concentrated HCl. Crystals were soaked first in harvest buffer containing 10 mM of the R-(+) or S-(-) warfarin enantiomer for 15 hours and then in buffer containing 20 mM of the same enantiomer for at least 24 hours.
Data collection and structure determination. X-ray diffraction data were collected at room temperature at station X-11 of the EMBL Outstation at DESY, Hamburg Germany ( Table 1 ). The data were indexed and measured with MOSFLM (A.
Leslie, personal communication). For both enantiomers, crystals of the HSAmyristate-warfarin complex were isomorphous with the HSA-myristate complex (11, 12 ). The protein model for this structure, stripped of its ligands, was used for initial phasing of the x-ray data. The model, split into its six sub-domains, was initially refined using a rigid body protocol in CNS (27) and then subjected to cycles of positional and B-factor refinement before calculation of initial F o -F c and 3F o -2F c maps. These maps were used to guide the positioning of the fatty-acid and warfarin ligands and bound waters and to make manual adjustments to the protein prior to further cycles of refinement. Details of the refinement statistics are summarised in Table 1 . Co-ordinates have been deposited with the Protein Data Bank (ID codes are given in Table 1 ). Figures depicting the structure were prepared using BOBSCRIPT (28) and RASTER3D (29).
Results

Structure determination
HSA-myristate complexes were prepared and crystallised as described previously and S-(-) warfarin bound to HSA-myristate were refined to 2.5 Å and have R free values of 25.4 % and 24.8 % respectively and good stereochemistry ( Table 1) .
Structure of the complex
The overall structures of the HSA-myristate-warfarin complexes are very similar to those reported for HSA-myristate and other HSA-fatty acid complexes (11,12) -there are only minor conformational changes in a number of side chains located at the drug binding site. As expected, warfarin binds within subdomain IIA in Sudlow's drug site I (Figure 3a) (10,13,32) and displaces the myristate molecule that binds to this domain (in fatty acid site 7, FA7) with relatively low affinity (12). In addition to the drug bound in IIA, there is a fragment of difference density adjacent to the myristate bound to subdomain IB at the same location observed for tri-iodobenzoic acid (11). The density would be large enough to encompass the coumarin moiety of warfarin and may represent a secondary binding site for the drug but there is no density for the other portions of the drug and a second ligand molecule has therefore not been incorporated into the model.
The warfarin binding pocket
The binding pocket is formed by the packing of all six helices of subdomain IIA Comparison with the structure of HSA-myristate-TIB (11) reveals differences in the ways that TIB and warfarin bind to site I. The heterocyclic coumarin moiety of warfarin binds in the same location as the benzyl ring of TIB. Though the planes of the aromatic rings are inclined at about 20° to each other, they make many of the same interactions with the walls of this part of the pocket and both drugs can also from specific hydrogen bonds with His 242. The presence of bulky iodine atoms projecting from the TIB benzyl group make it too wide to fit into the sub-pocket that accommodates the benzyl ring of warfarin.
Effect of fatty acids on warfarin binding
Our structural results offer a plausible explanation for the observation that Consistent with this hypothesis we have detected fatty acid binding at this site (designated FA7), in a manner that is suggestive of a low affinity interaction (primarily because of the absence of specific interactions between the protein and the fatty acid carboxylate group) (12). Thus we would only expect to find displacement of the drug by high levels of fatty acid.
Effect of pH on warfarin binding
Over the pH range 6-9 HSA undergoes a transition from the neutral (N) to the basic (B) form that is linked to an increase in the affinity of the protein for a number of site I ligands, including warfarin (which binds about threefold tighter 
Conclusions
Recently methods to study structural aspects of drug binding using engineered 
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